OUHSC Research News – Monday, December 13, 2021
Notices and Reminders
In alignment with the University’s closure for the upcoming Winter Break, the Office of the Vice President for Research (VPR) including ORA will be closed on December 23, 2021 through December 31, 2021, reopening on January 3, 2022.
Any proposals or other items due to sponsors during this time must be submitted to ORA within three business days before the campus closure dates. Any contracts expiring December 31, 2021 need to be in our office by December 13, 2021. Should you need urgent assistance during the holiday closure, please contact ORA at HSCORA@ouhsc.edu. All other matters will be addressed when the University reopens for regular business hours.
Effective October 1st, the NIH requires all NIH-funded clinical trials to complete clinical trial registration 21 days after enrollment of first participant and/or results reporting 12 months after trial actual primary completion date. NIH has now enhanced checks on non-compliance for these two requirements in the eRA System. Failure to comply with NIH timeline will delay your Research Performance Progress Report (RPPR) submission. NIH has also placed additional scrutiny on all aspects of RPPRs that has resulted in a significant increase in rejected reports from OUHSC investigators.
Because of these substantial changes and additional information requirements (including Other Support format), all RPPRs are now subject to additional review by ORA.
Effective January 1, 2022, ORA MUST receive RPPRs for review 3 business days prior to the sponsor deadline for single-project grants and 5 business days prior to the sponsor deadline for multi-project grants.
For more information on NIH enhanced checks on non-compliance, please see: https://nexus.od.nih.gov/all/2021/11/09/enhanced-checks-for-compliance-with-clinical-trial-registration-and-reporting-in-rppr/
We are fast approaching NIH January Deadline (i.e. January 25, 2022). Your assistance in notifying us of your intention to submit a proposal for the upcoming deadline and submitting the final proposal package according to the ORA proposal submission policy will help ensure a smooth and successful submission.
ORA Reminder: Effective October 1st, ORA requires applicants and recipients to use the updated Other Support format to submit with applications, Just-In-Time (JIT) and Research Performance Progress Reports (RPPRs).
Because of the substantial changes and additional information that needs to be included, all Key Personnel on RPPRs are expected to provide Other Support in the updated format for each RPPR, regardless of when Other Support was last submitted for key personnel. Failure to follow the appropriate format on or after October 1st, may delay processing your application/award by the ORA staff.
ORA Reminder: As a friendly reminder, please make sure you are carefully checking PeopleSoft and the budget justification to make sure OU Norman personnel are not included in the OUHSC personnel line. Failure to properly list the OUHSC vs Norman personnel in the budget preparation phase may result in a rebudget request from the sponsor, and could negatively impact processing of the award.
Requirements for Acknowledging NIH-Supported Research
NIH funded researchers are required to accurately acknowledge NIH funding in publications, press releases, or other documents about research that is funded by NIH in whole or in part. To comply with NIH requirements, recipients must include the following (as described in Communicating and Acknowledging Federal Funding):
Recipients should only acknowledge NIH awards on publications and other documents when the research activities that contributed to that publication directly arise from the award and are within the scope of the award being acknowledged. Please see the Communicating and Acknowledging Federal Funding and FAQs pages for more information on when, where, and how to acknowledge NIH funding.
Interested in becoming an IRB Member?
The OUHSC Institutional Review Board (IRB) currently has openings for new IRB members. The IRB reviews applications and reports for human research projects to ensure that the rights and welfare of human participants are protected and that risk of harm is minimized.
If you are interested in medical or social science research and would like to be involved with protecting the rights, safety and welfare of individuals who volunteer to participate in research, IRB membership may be for you. Current members have expressed that of all the committee’s they have participated in, the IRB has been the most rewarding. Members enjoy an increased understanding of research and exposure to cutting edge issues and current controversies in medical diagnostics and treatments. In addition, valuable collaboration may result from working closely with board members from a variety of disciplines.
If you are interested in learning more about IRB membership, please contact the HRPP Office at 405-271-2045 or email to email@example.com.
Workshops and Seminars
Data Science Workshop
Date: December 16, 2021 at 12:00 pm
Topic: Predicting 30-day Unplanned Re-admissions at OUMC Using an XG Boost Classifier Algorithm and the scikit-learn Library in Python.
Description: The Data Science Workshop meets every third Thursday (next meeting in Dec. 16th) at noon via zoom. It is based out of OUHSC and OMRF but participation is open to anyone doing data science including scientific computing. Our talks are recorded. Seventeen past talks can be found here: (https://mediasite.ouhsc.edu/Mediasite/Channel/python). Arnold Kanagwa of OU Health He will be giving a talk about the analysis of time series data. If you are interested in being on our mailing list and receiving the zoom link for the meeting, please contact Blaine Mooers (firstname.lastname@example.org).
OUHSC Funding Opportunities
American Cancer Society Institutional Research Grant (ACS-IRG) – Underrepresented Minority Focus
Description: The ACS-IRG is a unique source of funding entrusted to Stephenson Cancer Center (SCC) that provides seed money for early-stage faculty interested in cancer-related research - the ACS has provided SCC with supplemental monies that allow support for one pilot grant specifically directed towards an underrepresented minority (URM) investigator.
Eligibility: Full time Assistant Professors within six years of their first independent faculty appointment and with no active peer-reviewed research funding from national funding agencies (e.g. NIH, DOD, NSF, ACS) may apply.
Proposals Due: January 7, 2022
Link to Full Announcement: Please refer to the attached flyer for application link and guidelines.
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email email@example.com or firstname.lastname@example.org).
- Travere Therapeutics is seeking an academic research collaboration focused on polycystic kidney disease (ADPKD, ARPKD). Out of scope: drug repurposing, diagnostics. Preference is for opportunities with evidence of novel mechanism and POC data. Submission entails a 1-pg non-confidential summary of technology (deadline 1/5).
- A global pharmaceutical company (requested anonymity) is seeking innovative small molecule regulators of RNA transcripts that are highly selective toward their targets for treating immunologically based diseases. Out of scope: oligotherapeutics, gene therapy approaches, viral delivery. Submission entails a 1-pg non-confidential summary of technology (deadline 1/5).
- Bayer Crop Science is interested in collaborating with academia to identify novel and/or engineered protein candidates that can be produced in plant cell cultures or transformed plant systems for applications in food, agriculture, sustainability, consumer health, pharmaceuticals or other industries. Out of scope: products with a small potential market. Submission entails a 1-pg non-confidential summary of technology (deadline 1/12).
- Roivant Sciences is seeking key opinion leaders/advisors to collaborate in developing a universal influenza vaccine program based on differentiated RNA technology. Areas of interest include delivery systems for RNA, adjuvants, and modified nucleosides. RNA-based technologies that have no potential application to respiratory diseases are out of scope. Submission entails a 1-pg non-confidential summary of technology (deadline 1/12).
- NCCIH Announces Availability of Frequently Asked Questions (FAQs) for HEAL Sickle Cell Disease Pain Management Funding Opportunities RFA-AT-22-004 and RFA-AT-22-005
- Pre-Application Webinar for RFA-CA-21-060, RFA-CA-21-061, and RFA-CA-21-062: "The NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers"
- Pre-Application Webinar for NCI's Innovative Molecular Analysis Technologies (IMAT) Innovative Technologies Funding Opportunities (RFA-CA-22-001, RFA-CA-22-003)
- Request for Information on Proposed Updates and Long-Term Considerations for the NIH Genomic Data Sharing Policy
- Notice of Change to Eligibility Information in PAR-21-351 "NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)"
- Notice of Early Expiration of PAR-19-078, Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)"
- Notice of Early Expiration of PAR-19-079, Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)"
- Notice of Early Expiration of PA-19-077, Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)"
- Notice of NIAMS' Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"
- Notice to Extend NOT-AR-20-005, "Notice of Special Interest: Promoting research opportunities on HIV/AIDS in NIAMS"
- Notice of Clarification of Award Budget Instructions for Specific Aims in RFA-ES-21-007, Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)
- Notice of NICHD Participation in NOT-OD-20-054, "Notice of Special Interest: Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars"
- Notice of NICHD Participation in NOT-OD-20-055, "Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards"
- Notice of Change to Key Dates for PAR-19-261, "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)"
- Notice of Change in Eligible Organizations for PAR-21-312, "Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed)"
- Notice of Change of the Locus of Review and Application Types Allowed for PAR-22-035, "Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)"
- Notice of Change of the Locus of Review and Application Types Allowed for PAR-22-036, "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)"
- Notice of Participation of the National Institute of Nursing Research (NINR) in PAR-21-287, Effectiveness of School-Based Health Centers to Advance Health Equity (R01 Clinical Trial Optional)
- Notice of Correction to Award Information for RFA-RM-22-006, " Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed)"
- Notice of Change to Participant Eligibility, Participant Costs and Other Attachments to Funding Opportunity Announcement PAR-21-339, Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Program (R25)
- Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
- Notice of Intent to Publish a Funding Opportunity Announcement for NIDCD National Human Ear Resource Network (U24)
- Notice of Intent to Publish a Funding Opportunity Announcement for NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinical Trial Not Allowed)
- Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Comprehensive Centers for Human and Non-Human Primate Brain (UM1 Clinical Trial Not Allowed)
- Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Comprehensive Centers for Mouse Brain (UM1 Clinical Trial Not Allowed)
- Notice of Intent to Publish a Funding Opportunity Announcement for Research on Community Level Interventions to Prevent Firearm and Related Violence, Injury and Mortality
- Notice of Special Interest: Administrative Supplements and Urgent Competitive Revisions on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA
- Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity
- Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery
- Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology
- Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs
- Notice of Special Interest (NOSI): KC Donnelly Externship (Admin Supp Clinical Trial Not Allowed)
- Notice of Special Interest (NOSI): Administrative Supplements for Research on Sex and/or Gender Influences (Admin Supp Clinical Trial Optional)
- Notice of Special Interest (NOSI): Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)
- Notice of Special Interest (NOSI): Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp Clinical Trial Optional)
- Notice of Special Interest (NOSI): Availability of Administrative Supplements for Helping to End Addiction Long-term (HEAL) Initiative awardees to make data Findable, Accessible, Interoperable, and Reusable (FAIR) through the HEAL Data Ecosystem
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
- Limited Competition: Research Resource for the National Swine Resource and Research Center (U42 Clinical Trial Not Allowed)
Application Receipt Date(s): September 25, 2023
- Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
Application Receipt Date(s): Multiple dates, see announcement.
- Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
Application Receipt Date(s): January 07, 2025
- NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)
Application Receipt Date(s): June 14, 2024
- Continuation or Revision of NIDCR Clinical Trial Implementation Cooperative Agreement (UH3 Clinical Trial Required)
Application Receipt Date(s): Multiple dates, see announcement.
- High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
Application Receipt Date(s): October 30, 2024
- Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)
Application Receipt Date(s): May 07, 2025
- Resource Networks for Protein Polymorphisms in Alzheimers Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed)
Application Receipt Date(s): January 10, 2022
- National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD) (U2C - Clinical Trial Not Allowed)
Application Receipt Date(s): March 08, 2022
- New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)
Application Receipt Date(s): Multiple dates, see announcement.
- Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed)
Application Receipt Date(s): March 24, 2022
- Coordinating Unit for the National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD) (U24 - Clinical Trial Not Allowed)
Application Receipt Date(s): March 08, 2022
- Conformance with the Egg Regulatory Program Standards (U2F) [Clinical Trial Not Allowed]
Application Receipt Date(s): January 31, 2022
- Child Health Research Career Development Award (CHRCDA) Program (K12 Clinical Trial Not Allowed)
Application Receipt Date(s): March 30, 2022
- Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Scientific Leadership Center (UM2 Clinical Trial Optional)
Application Receipt Date(s): March 31, 2022
- Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional)
Application Receipt Date(s): March 31, 2022
- BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)
Application Receipt Date(s): October 11, 2024
Other Funding Opportunities
NIH technology accelerator challenge for maternal health
Description: The National Institute of Biomedical Imaging and Bioengineering (NIBIB), with the support of its partners, is offering up to $1,000,000 in cash prizes for innovative diagnostic technologies to help improve maternal health around the world.
The NIH Technology Accelerator Challenge for Maternal Health (NTAC: Maternal Health) seeks to spur and reward the development of prototypes for low-cost, point-of-care molecular, cellular, and/or metabolic sensing and diagnostic technologies to guide rapid clinical decision-making, improve patient outcomes, and ultimately prevent maternal morbidity and mortality.
To win NTAC: Maternal Health, participants must: (1) Submit their design for a point-of-care diagnostic test or platform technology with initial feasibility data or references addressing at least two of the four priority conditions listed below affecting maternal health during antenatal and intrapartum periods; and (2) Submit a robust description of the proposed path for translation and further development of the diagnostic technology for use in global health settings. Additionally, diagnostics should be fully integrated digital health platforms. The four priority conditions and specific examples are as follows:
- Infection: viral, bacterial, or parasitic infections; sepsis; post-procedural infections
- Hypertensive disease: pre-eclampsia; eclampsia
- Hemorrhage: acute anemia; iron deficiency anemia; coagulopathy
- Placental issues: angiogenic or other markers of placental disruption
Proposals Due: April 1, 2022
Link to Full Announcement: https://venturewell.org/ntac/
Telligen Community Initiative (TCI) philanthropy - 2022 REQUEST FOR PROPOSALS
Description: Grants of up to $50,000 to Illinois, Iowa, Colorado, and Oklahoma nonprofits, schools, and agencies for programs that support creative ways to bring innovation and equity to the health sector and recruiting and generating pathways to a high-quality health care workforce. Programs can also emphasize novel approaches to positively address the social determinants of health.
All current TCI grants are for periods of one year. Cycle 1 awardees (OK or CO) begin on June 1, 2022.
Proposals Due: February 28, 2022
Link to Full Announcement: http://telligenci.org/grants
OKLAHOMA NSF EPSCoR Research Seed Grant Funding Opportunity
Description: The Oklahoma NSF EPSCoR program is announcing the availability of funding to stimulate high-risk, high-impact, and potentially transformative research to develop and test science-based solutions for complex (“wicked”) problems at the intersection of land use, water availability, and infrastructure in OK. Seed Grant proposals will be accepted by OK NSF EPSCoR from any Oklahoma institution of higher education. Funding will be awarded for projects of up to 1-year duration. The maximum award amount for a single award is $75,000; however, smaller proposals are encouraged.
Proposals Due: November 17, 2021
Link to Full Announcement: http://www.okepscor.org/sites/default/files/u6/2022%20OK%20NSF%20EPSCoR%20Seed%20Grant%20Guidance.pdf
NSF Integrative Research in Biology (IntBIO)
Description: This solicitation invites submission of collaborative proposals that tackle bold questions in biology and require an integrated approach to make substantive progress. Integrative biological research spans subdisciplines and incorporates cutting-edge methods, tools, and concepts from each to produce groundbreaking biological discovery. The research should be synergistic and produce novel, holistic understanding of how biological systems function and interact across different scales of organization, e.g., from molecules to cells, tissues to organisms, species to ecosystems and the entire Earth. Such knowledge is critical to inform solutions to societal challenges, including natural resource management, resilience to environmental change, and global food security. Outcomes from integrative research will also inform and guide the development of new technologies that drive the nation's bioeconomy.
Proposals Due: January 25, 2022
Link to Full Announcement: https://www.nsf.gov/pubs/2021/nsf21622/nsf21622.htm
NSF Major Research Instrumentation Program: (MRI)
Description: The Major Research Instrumentation (MRI) Program serves to increase access to multi-user scientific and engineering instrumentation for research and research training in our Nation's institutions of higher education and not-for-profit scientific/engineering research organizations. An MRI award supports the acquisition or development of a multi-user research instrument that is, in general, too costly and/or not appropriate for support through other NSF programs.
Proposals Due: January 19, 2022
Link to Full Announcement: https://www.nsf.gov/pubs/2018/nsf18513/nsf18513.pdf
Diabetes Research Wellness Foundation – Research Grants
Description: DRWF accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to $50,000 per year for up to 2 years. If the proposed research is within an area of primary interest and is judged as having high scientific merit by the Foundation’s advisors, the Board of Directors may make special grant awards that exceed the stated maximum. Currently, the Foundation’s area of primary interest and focus are islet cell transplantation, macrovascular disease & neuropathy. All other research proposals will not be reviewed.
Proposals Due: December 30, 2021
Link to Full Announcement: https://www.diabeteswellness.net/apply-funding
Mary Kay Ash Foundation 2022 Cancer Research Grants
Description: The Mary Kay Ash FoundationSM is a non-profit public foundation, which focuses on funding research for innovative grants for translational research of cancers affecting women (ovarian, uterine, breast, endometrial or cervical cancer among others). Translational research is broadly defined as research that will provide a scientific link between laboratory research and the clinic. Such research would lead to improvement in diagnosis, prognosis, prevention, or treatment of the cancer. The Foundation is pleased to invite your institution to submit one grant proposal. Please note only one grant application will be accepted from each accredited, invited institution.
The grant will be up to $100,000 (combined direct and indirect costs) for a two-year period. The Foundation anticipates funding between 10 and 15 grants. Please review the attached RFP with FAQs section as well as the Applicant User Guide for additional information.
Proposals Due: February 4, 2022 at 11:59 PM (CT)
Please complete your application here: https://apply.yourcausegrants.com/apply/programs/7d085160-a542-4415-bea4-1fbe139b51ee*
Please reach out to Julia Santosuosso if you have any questions at Julia.Santosuosso@mkcorp.com.
The Mselanoma Research Alliance (MRA) 2021-2022 Request for Proposal
Team Science Award Full Proposals Due (from invited applicants) Due: January 19, 2022
Description: MRA anticipates supporting at least $12.8 million in new funding. Proposals will be accepted for Team Science, Academic-Industry Partnership, Young Investigator, and Pilot Awards. Special Opportunities are also available in immunotherapy, women in research, and patient-centric clinical trials. MRA encourages applications from a diverse pool of investigators. Full descriptions of each award opportunity offered, including all Special Opportunity Awards, as well as eligibility criteria and instructions can be found on the MRA website at CureMelanoma.org/RFP
Proposals should be submitted via the proposalCENTRAL online application tool: https://proposalcentral.com/
Oklahoma Center for Adult Stem Cell Research (OCASCR)
Grant Deadline: January 28, 2022